目的 探讨血清中人基质裂解素(ST2)水平的变化在炎症性肠病(IBD)活动性评估中的意义.方法 ELISA法(酶联免疫吸附测定)检测IBD患者45例,其中UC患者29例,CD患者16例,已排除IBD的其他胃肠疾病(包括主诉不明原因腹痛、腹泻、胃肠炎)的患者24例和15例健康人血清中ST2水平,20例IBD患者检测治疗前后ST2水平的改变.结果 IBD活动期血清中ST2水平为(1884.72±338.38) pg/mL,显著高于缓解期(1292.27±347.73) pg/mL和健康对照组(1 026.85±382.35) pg/mL,血清ST2水平在治疗前和治疗后(t=4.067,P＜0.01)、UC患者和CD患者(t=2.202,P=0.035)之间差异具有统计学意义.结论 血清中ST2水平可作为炎症性肠病活动性评估和临床治疗效果的评价指标.%Objective To investigate the clinical significance of ST2 expression in inflammatory bowel disease (IBD). Methods Serum samples were obtained from 29 patients with UC, 16 patients with CD, 24 patients with other non-IBD gastrointestinal conditions and 15 healthy controls. Levels and positivity rates of ST2 were determined by enzyme-linked immunosorbent assay ( ELISA). The level of ST2 before and after treatment was measured in 20 cases of IBD patients. Results The ST2 level of patients with active IBD was significantly higher (1884. 72 ±338.38) pg/mL than that of patients with inactive IBD( 1 292. 27 ± 347.73 ) pg/mL and healthy controls(1026. 85 ± 382.35 ) pg/mL. The serum level of ST2 between UC and CD( P < 0. 05 ) , before treatment and after treatment( P < 0.01 ) was statistically significant difference. Conclusion The level of ST2 can be used as indicator for predicting the activity and the effectiveness of IBD.
展开▼
